en · de · es · fr · pt
cardarine-notes.peptides4800.com › News › Preclinical Findings And Safety Signals — Hands-On Walkthrough

Preclinical Findings And Safety Signals — Hands-On Walkthrough

By Editorial Desk · published 2026-01-12 · last reviewed 2026-02-27 · News

Everything below concerns PPARδ agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2026-02-27. Numbers and descriptions here follow the published literature rather than marketing material.

Preclinical Findings and Safety Signals

Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.

Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.

Background and Regulatory Status

Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.

Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.

Cardarine at a glance

PropertyValueNotes
Primary targetPPARδ (NR1C2)Nuclear receptor involved in lipid metabolism
Preclinical effectIncreased fatty acid oxidationObserved in rodent studies
Key safety signalTumors in rodents after long-term exposureContributed to halted clinical development
Human trial statusNo approved product; development stoppedLimited short-term metabolic data
Sport regulatory statusProhibited at all timesWADA hormone and metabolic modulators class

Mechanism and Research Context

In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.

GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.

Related pages on this site

Identity and Pharmacological Classification

Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.

Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.

PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.

Detection, Regulation, and Quality Context

Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.

Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.

Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.

Supporting material

== Diseases related to hemoglobin == Hemoglobin deficiency can be caused either by a decreased amount of hemoglobin molecules, as in anemia, or by decreased ability of each molecule to bind oxygen at the same partial pressure of oxygen. Hemoglobinopathies (genetic defects resulting in abnormal structure of the hemoglobin molecule) may cause both. In any case, hemoglobin deficiency decreases blood oxygen-carrying capacity. Hemoglobin deficiency is, in general, strictly distinguished from hypoxemia, defined as decreased partial pressure of oxygen in blood, although both are causes of hypoxia (insufficient oxygen supply to tissues). Other common causes of low hemoglobin include loss of blood, nutritional deficiency, bone marrow problems, chemotherapy, kidney failure, or abnormal hemoglobin (such as that of sickle-cell disease). The ability of each hemoglobin molecule to carry oxygen is normally modified by altered blood pH or CO2, causing an altered oxygen–hemoglobin dissociation curve. However, it can also be pathologically altered in, e.g., carbon monoxide poisoning. Decrease of hemoglobin, with or without an absolute decrease of red blood cells, leads to symptoms of anemia. Anemia has many different causes, although iron deficiency and its resultant iron deficiency anemia are the most common causes in the Western world. As absence of iron decreases heme synthesis, red blood cells in iron deficiency anemia are hypochromic (lacking the red hemoglobin pigment) and microcytic (smaller than normal). Other anemias are rarer.

Harman trademarked the phrase "It's finger lickin' good", which eventually became the company slogan. He also introduced the "bucket meal" in 1957 (14 pieces of chicken, five bread rolls and a pint of gravy in a cardboard bucket). Serving their signature meal in a paper bucket was to become an iconic feature of the company. By 1963, there were 600 KFC restaurants, making the company the largest fast food operation in the United States. KFC popularized chicken in the fast food industry, diversifying the market by challenging the dominance of the hamburger. With significant growth in tow, the fledgling Kentucky Fried Chicken decided in 1964 that they would begin offering franchise opportunities beyond the Atlantic, and landed on the United Kingdom as its entry point into Europe. As such, the first British KFC eatery opened its doors at 92 Fishergate in Preston, Lancashire, on May 1, 1965, and still operates today. Pat Grace met with Sanders at his holiday home near Toronto, Canada, and agreed to franchise the brand in Ireland. In 1970 Grace returned to Ireland after a number of years in Canada to open his first Kentucky Fried Chicken restaurants in Phibsboro shopping center in Dublin. Eventually he opened another six restaurants located in Dublin, Limerick and Cork. After disagreements over cost cutting with KFC management in the early 1980s, the Irish restaurants were renamed to Pat Grace's Famous Fried Chicken reportedly retaining the original recipe. These stores were closed in the late 1980s.

When they had opened his tomb and they thought his body would stink because of the amount of time that had elapsed since it had been buried, such a sweet fragrant odor like a diversity of flowers flowed forth, and the whole church was filled with little drops of balsam. And when the brothers who had come to see him from the neighboring province... removed the clothes in which he had been buried because they wanted to change them wishing to dress him in new clothes, they found on his forearms the sign of the dominical cross, bearing the likeness of a red color. It was evident to all the faithful that this was given to be understood that while he lived he bore the arms of Christ in his heart, therefore, Christ's stigmata were revealed on the body of the dead man.

Thereafter, the amount of carbon-14 in organic matter decreases according to decay processes that may also be independently cross-checked by other means (such as checking the carbon-14 in individual tree rings, for example).

5α-Reductase inhibitors are inhibitors of the enzyme 5α-reductase, and are a type of specific androgen synthesis inhibitor. 5α-Reductase is an enzyme that is responsible for the conversion of testosterone into the more potent androgen dihydrotestosterone (DHT). There are three different isoforms of 5α-reductase, types 1, 2, and 3, and these three isoforms show different patterns of expression in the body. Relative to testosterone, DHT is about 2.5- to 10-fold more potent as an agonist of the androgen receptor. As such, 5α-reductase serves to considerably potentiate the effects of testosterone. However, 5α-reductase is expressed only in specific tissues, such as skin, hair follicles, and the prostate gland, and for this reason, conversion of testosterone into DHT happens only in certain parts of the body. Furthermore, circulating levels of total and free DHT in men are very low at about one-tenth and one-twentieth those of testosterone, respectively, and DHT is efficiently inactivated into weak androgens in various tissues such as muscle, fat, and liver. As such, it is thought that DHT plays little role as a systemic androgen hormone and serves more as a means of locally potentiating the androgenic effects of testosterone in a tissue-specific manner. Conversion of testosterone into DHT by 5α-reductase plays an important role in male reproductive system development and maintenance (specifically of the penis, scrotum, prostate gland, and seminal vesicles), male-pattern facial/body hair growth, and scalp hair loss, but has little role in other aspects of masculinization.

Sources: en.wikipedia.org

Supporting material

Jürgen Sundermann (28 May 1991 – 30 June 1993) Bernd Stange (1 July 1993 – 21 February 1994) Jürgen Sundermann (22 February 1994 – 8 April 1994) Damian Halata (9 April 1994 – 30 June 1994) Tony Woodcock (1 July 1994 – 30 October 1994) August "Gustl" Starek (31 October 1994 – 30 May 1996) Damian Halata (1 June 1996 – 30 June 1996) Sigfried "Siggi" Held (1 July 1996 – 7 October 1997) Damian Halata (8 October 1997 – 30 June 1998) Hans-Ulrich "Uli" Thomale (1 July 1998 – 28 March 1999) Dragoslav Stepanović (29 March 1999 – 29 August 1999) Joachim Steffens (30 August 1999 – 22 July 2001) Hans-Jürgen "Dixie" Dörner (23 July 2001 – 26 March 2003) Detlef Schößler (27 March 2003 – 3 June 2003) Hermann Andreev (24 June 2003 – 19 March 2004) Michael Breitkopf and Jörg Engelmann (20 March 2004 – 22 April 2004) Mike Sadlo (23 April 2004 – 30 June 2004) – Player/manager 1. FC Lok Leipzig

== Reaction == In the catalytic cycle, the immediate one-electron oxidized product is monodehydroascorbate (MDHA). MDHA is either enzymatically reduced back to ascorbate by monodehydroascorbate reductase (MDAR) or two MDHA molecules disproportionate to ascorbate and dehydroascorbate (DHA).

=== Anticodon === An anticodon is a unit of three nucleotides corresponding to the three bases of an mRNA codon. Each tRNA has a distinct anticodon triplet sequence that can form 3 complementary base pairs to one or more codons for an amino acid. Some anticodons pair with more than one codon due to wobble base pairing. Frequently, the first nucleotide of the anticodon is one not found on mRNA: inosine, which can hydrogen bond to more than one base in the corresponding codon position. In genetic code, it is common for a single amino acid to be specified by all four third-position possibilities, or at least by both pyrimidines and purines; for example, the amino acid glycine is coded for by the codon sequences GGU, GGC, GGA, and GGG. Other modified nucleotides may also appear at the first anticodon position—sometimes known as the "wobble position"—resulting in subtle changes to the genetic code, as for example in mitochondria. The possibility of wobble bases reduces the number of tRNA types required: instead of 61 types with one for each sense codon of the standard genetic code), only 31 tRNAs are required to translate, unambiguously, all 61 sense codons.

=== Layne Staley Day in Seattle === On August 22, 2019, which would have been Staley's 52nd birthday, Seattle mayor Jenny Durkan officially proclaimed that day as "Layne Staley Day" in the city in honor of Staley's contributions to the world of music. The day was also a call to attention to the Layne Staley Memorial Fund, established by his parents in 2002.

The temperature at which dew forms on a clean surface is directly related to the vapor pressure of the air. Dew point hygrometers work by placing a mirror over a closed sample chamber. The mirror is cooled until the dew point temperature is measured by means of an optical sensor. This temperature is then used to find the relative humidity of the chamber using psychrometrics charts. This method is theoretically the most accurate (+/- 0.003 aw) and often the fastest. The sensor requires cleaning if debris accumulates on the mirror.

Sources: en.wikipedia.org

Frequently asked questions

What did animal studies show?

Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.

Has cardarine been tested in humans?

Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.

Does cardarine improve athletic performance in people?

Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.

Is cardarine approved for human use?

No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.

Network